MedCity News August 2, 2024
The FDA approved Adaptimmune Therapeutics’ Tecelra as a treatment for advanced cases of synovial sarcoma. It’s the first engineered cell therapy approved for treating a solid tumor.
Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory decision that makes the new product the first engineered cell therapy approved for treating a solid tumor.
Known in development as afamitresgene autoleucel, or afami-cel, the new Adaptimmune product will be marketed under the brand name Tecelra.
“Adaptimmune was founded on the conviction that cell therapy would revolutionize the treatment of cancer,” CEO Adrian Rawcliffe said, speaking during a Friday conference call. “This has been...
Today's Sponsors
Today's Sponsor